Health & Fitness
Health and Fitness
Health and Fitness
Wed, June 9, 2010
Tue, June 8, 2010 Neostem Set to Become First Fully Commercial Stem Cell Medicine Play
LOS ANGELES, CA--(Marketwire - June 8, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Neostem's (
According to the published report, in recent months, the company has been busy expanding their network of adult stem cell collection centers in the United States and now they are preparing to launch commercial activities for at least two highly profitable adult stem cells therapies in China and Taiwan.
Neostem's VSELs™ play a pivotal role in the normal rejuvenation of adult tissues as well as involvement in regeneration of damaged organs, and now that the company has harnessed and patented the regenerative potential of these cells, commercial applications to decelerate the aging process are ready to be monetized. In mainland China alone, at least 1000 people have joined the waiting list for either orthopedic or cosmetic treatments using the company's VSEL™ stem cells -- which share some properties with embryonic stem cells, such as large expansion capacity and expression of Oct-4 and Nanog.
Early indications are that the price for the cosmetic medicine treatments using the company's technology, for example, will range between $5,000 and $10,000 U.S. dollars. With twenty percent of those costs payable as royalties to Neostem, the profit potential is analyzed in detail in the special report.
VSEL™ technology-based therapies have applications in orthopedic (bone), cardio and countless other spaces.
Investors can find the full report at BioMedReports.Com
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
[ http://biomedreports.com/fda-calendar/fda-calendar.html ]
About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.
For more biomedical sector and investment news go to [ http://BioMedReports.com ]
